clinical trial · NCT07784101
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·not yet recruiting·n = 280
Relapsed or Refractory Mantle Cell Lymphoma (MCL)ICP-248PirtobrutinibOrelabrutinib
brief summary
This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).
started
Oct 1, 2026
primary completion
Oct 1, 2032
completion
Dec 1, 2033
last updated
Aug 25, 2026
official title
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol